|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date20 Mar 2008 |
一项评估盐酸苯达莫司汀用于对利妥昔单抗治疗耐药的惰性非霍奇金淋巴瘤(NHL)中国患者的开放研究
[Translation] An open-label study evaluating bendamustine hydrochloride in Chinese patients with indolent non-Hodgkin lymphoma (NHL) resistant to rituximab
本研究的主要目的是确定使用利妥昔单抗或含利妥昔单抗的治疗后疾病出现进展的惰性非霍奇金淋巴瘤(NHL)患者对苯达莫司汀治疗的整体缓解率(ORR),包括完全缓解(CR)、部分缓解(PR)。
[Translation] The primary objective of this study was to determine the overall response rate (ORR), including complete response (CR) and partial response (PR), to bendamustine in patients with indolent non-Hodgkin lymphoma (NHL) who had disease progression after rituximab or rituximab-containing therapy.
100 Clinical Results associated with Beijing Pinxin Fama Medicine Technology Development Co., Ltd.
0 Patents (Medical) associated with Beijing Pinxin Fama Medicine Technology Development Co., Ltd.
100 Deals associated with Beijing Pinxin Fama Medicine Technology Development Co., Ltd.
100 Translational Medicine associated with Beijing Pinxin Fama Medicine Technology Development Co., Ltd.